Search

Chlorphenesin

Islatravir

[A275492] On April 21, 2026, the FDA approved the first fixed-dose combination containing islatravir (0.25 mg) and the NNRTI doravirine (100 mg), marketed as IDVYNSO, as a complete once-daily regimen for

Alosetron

Alosetron has an antagonist action on the 5-HT3 receptors and thus may modulate serotonin-sensitive gastrointestinal (GI) processes. … Alosetron was voluntarily withdrawn from the US market in November 2000 by the manufacturer due to numerous reports of severe adverse effects including ischemic colitis, severely obstructed or ruptured

Mafenide

[L36773] In 1998, mafenide acetate was approved under the FDA’s accelerated approval regulations. … In November 2022, the use of mafenide acetate (powder for 5% topical solution) was withdrawn by the FDA due to an unresolved confirmatory study required to fulfill the accelerated approval requirements

Misoprostol

[A181586] Misoprostol was granted FDA approval on 27 December 1988.[L7616]

Medical air

Medical air is supplied by a special air compressor to patient care areas using clean outside air.

Quaternium-15

Quaternium-15 is a quaternary ammonium salt used as a surfactant and preservative in many products including cosmetics. … In 2005, Quaternium-15 was named in the top 15 most frequently positive allergens identified in patch tests by the North American Contact Dermatitis Group (NACDG)[A34326].

Cefoperazone

While its clinical use has been discontinued in the U.S., cefoperazone is available in several European countries most commonly under the product name, Sulperazon.

Asparaginase Escherichia coli

It is available as intramuscular or intravenous injections. … Asparaginase from _E. coli_ has clinically shown to exhibit antitumor actions in models of leukaemias [A31996, A31997].

Turoctocog alfa

[A31504] It was developped by Novo Nordisk and FDA approved in October 16, 2013.[L1104]